The pressure on the pharmaceutical company R&D has never been greater.
It is estimated that $100 billion worth of products will face patent expiry
by 2005.
Of this, $37 billion represent blockbuster drugs, whose revenues are becoming
threatened as generic competition takes away market share. Combined with increasing
global pressure for cost containment by healthcare providers, this threat is
driving the pharmaceutical industry to look to its future strategy to drive
expansion.
The NEW Reuters Business Insight report, The Top 12 Pharmaceutical Companies,
provides a detailed analysis of the 12 leading ethical pharmaceutical company
strategies in 2001, showing how each company is seeking to sustain growth over
the next five years. The Top 12 Pharmaceutical Companies, written by Datamonitor's
Competitive Intelligence team, provides insight into the interaction between
the industry's global giants. The report will help you understand what has driven
sales to date and what future potential exists for current R&D portfolios.
Each companies' position in 2006 is assessed, allowing each to be benchmarked
against its competitors.
• The pharmaceutical revenues generated by and projected for each company
between 1996 and 2006
• Geographic expansion strategies, of each of the 12 companies, identifying
where future sales will be derived from
• A SWOT analysis of each company and summary of future potential (see
diagram)
• Analysis of the key strategies that have propelled these companies to
their market-leading positions
• Predictions of the future organic and merger and acquisition-based growth
potential
• Key in- and out-licensing opportunities
